Clene Inc. has announced its financial results for the third quarter of 2026, marking a pivotal moment for the company as it seeks to revolutionize treatment options for neurodegenerative diseases. The announcement, made on November 4, 2026, includes a significant update regarding the company’s New Drug Application (NDA) for its lead product, CNM-Au8, aimed at treating amyotrophic lateral sclerosis (ALS).

Rob Etherington, President and CEO of Clene, emphasized the importance of the NDA submission, stating, “Clene’s submission of the NDA for CNM-Au8 is a pivotal achievement for the company and, more importantly, a meaningful step toward bringing new treatment options to people living with ALS.” This submission is supported by clinical data and biomarker results from previous trials, showcasing the potential of CNM-Au8 to improve patient outcomes.

Founded in Salt Lake City, Clene Inc. operates in the pharmaceutical preparations sector, specifically focusing on developing innovative treatments for neurodegenerative conditions. The company trades on the Nasdaq under the ticker symbol CLNN and has been actively pursuing advancements in its clinical programs.

The recent SEC filing reveals that Clene has made significant strides in its operational and financial health. The company completed a $4.0 million registered direct offering in September 2026, which is expected to fund operations through mid-first quarter 2027. This funding is crucial as it prepares for the upcoming Phase 3 RESTORE-ALS trial, set to begin in the second quarter of 2027.

In the third quarter, Clene reported cash and cash equivalents totaling $9.9 million, an increase from $5.2 million at the end of the previous year. However, the company also noted a net cash usage of $11.7 million in operating activities during this period, indicating the ongoing costs associated with its clinical development efforts.

Clene’s NDA submission to the U.S. Food and Drug Administration (FDA) is a significant milestone in its journey to bring CNM-Au8 to market. The company believes that this drug has the potential to restore and protect neuronal health, which is critical for patients suffering from ALS. Etherington expressed optimism about the FDA’s engagement throughout the NDA process and the company’s commitment to working closely with the agency.

As Clene Inc. continues to navigate the complexities of drug development and regulatory approval, its recent updates may influence the broader pharmaceutical preparations industry. Competitors will be closely watching Clene’s progress, particularly in the context of ALS treatment options and the potential for accelerated approval pathways.

The filing does not specify what happens next, but the anticipation surrounding the FDA’s review process and the initiation of the Phase 3 trial will likely keep stakeholders engaged.